Reported Earlier, NeuroBo's Novel Drug Shows Results for Weight Loss at ADA 2024
Reported Earlier, NeuroBo's Novel Drug Shows Results for Weight Loss at ADA 2024
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models. Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center, will present the data today, in a poster at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21-24, in Orlando, Florida.
NeuroBo制药公司（纳斯达克股票代码：NRBO）是一家专注于心脏代谢性疾病转化的临床生物技术公司，今天宣布了临床前数据，表明DA-1726，一种新型的双氧铜酮肽（OXM）类似物激动剂，其功能为胰高血糖素样肽-1受体（GLP1R）和胰高血糖素受体（GCGR），与survodutide在临床前模型中相比，显示出在减重、保持瘦体重和降低脂质方面的优越性。来自东亚生命科学研究院的首席研究员金泰亨（Tae-Hyoung Kim）将于今天在佛罗里达州奥兰多举行的美国糖尿病协会（ADA）第84届科学会议的海报展示上呈现这些数据。